Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with ...

Four oral glucagon-like peptide-1 receptor (GLP1R) drugs, currently under Phase III trials, are in the race for approval, ...

GLP-1R injectable drugs are effective in treating obesity, but their success points to a gap in the market: oral alternatives ...

The obesity prevalence continues to increase, with predictors of weight loss including type 2 diabetes status, high BMI, and older age.

GLP-1 receptor (GLP-1R) products have gained immense popularity in recent years, and four are currently approved in major ...

Polycystic Ovary Syndrome, or PCOS, is a common condition that affects women of reproductive age with impact from adolescence ...

With expected sales for GLP1Rs in obesity estimated to surpass $126 billion by 2030, this drug category presents a lucrative ...

Novo Nordisk A/S (NYSE:NVO) is advancing its research on a pioneering hybrid drug, CagriSema. This drug merges semaglutide ...